share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改注册声明表
美股SEC公告 ·  04/22 12:38

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the registration of common stock shares that may be sold by a selling stockholder, Armistice Capital, LLC. The shares in question are issuable upon the exercise of previously issued warrants, including the July 2022 Common Warrants, December 2022 Common Warrants, April 2023 Common Warrants, and December 2023 Common Warrants. The selling stockholder may sell the shares through various methods such as block trades, private transactions, or on the open market. The filing also includes details on indemnification agreements, recent unregistered sales of securities, and the potential impact of the shares' sale on the company's control. The registration allows the selling stockholder to publicly sell their shares, but does not necessarily indicate that they will do so. The company will not receive any proceeds from the sale of shares by the selling stockholder.
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the registration of common stock shares that may be sold by a selling stockholder, Armistice Capital, LLC. The shares in question are issuable upon the exercise of previously issued warrants, including the July 2022 Common Warrants, December 2022 Common Warrants, April 2023 Common Warrants, and December 2023 Common Warrants. The selling stockholder may sell the shares through various methods such as block trades, private transactions, or on the open market. The filing also includes details on indemnification agreements, recent unregistered sales of securities, and the potential impact of the shares' sale on the company's control. The registration allows the selling stockholder to publicly sell their shares, but does not necessarily indicate that they will do so. The company will not receive any proceeds from the sale of shares by the selling stockholder.
180 生命科学公司已于 2024 年 4 月 19 日向美国证券交易委员会 (SEC) 提交了对 S-1 表格注册声明的生效后修正案。该修正案涉及出售股东Armistice Capital, LLC可以出售的普通股的注册。有关股票可在行使先前发行的认股权证后发行，包括2022年7月的普通认股权证、2022年12月的普通认股权证、2023年4月的普通认股权证和2023年12月的普通认股权证。卖出股东可以通过各种方式出售股票，例如大宗交易，私人交易或公开市场。该文件还包括有关赔偿协议、最近未注册证券销售以及股票出售对公司控制权的潜在影响的详细信息。注册允许出售股东公开出售其股票，但不一定表示他们会这样做。该公司不会从出售股票的股东获得任何收益。
180 生命科学公司已于 2024 年 4 月 19 日向美国证券交易委员会 (SEC) 提交了对 S-1 表格注册声明的生效后修正案。该修正案涉及出售股东Armistice Capital, LLC可以出售的普通股的注册。有关股票可在行使先前发行的认股权证后发行，包括2022年7月的普通认股权证、2022年12月的普通认股权证、2023年4月的普通认股权证和2023年12月的普通认股权证。卖出股东可以通过各种方式出售股票，例如大宗交易，私人交易或公开市场。该文件还包括有关赔偿协议、最近未注册证券销售以及股票出售对公司控制权的潜在影响的详细信息。注册允许出售股东公开出售其股票，但不一定表示他们会这样做。该公司不会从出售股票的股东获得任何收益。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间